重组人脑利钠肽联合左西孟旦对急性失代偿性心力衰竭的临床研究

The Clinical Investigation of Recombinant Human Brain Natriuretic Peptide combined with Levosimendan for Patients with Acute Decompensated Heart Failure

目的:探讨重组人脑利钠(rhBNP)联合左西孟旦治疗急性失代偿性心力衰竭患者的临床疗效及安全性。方法:将2015年1月-2016年1月我院收治的急性失代偿性心力衰竭患者83例随机分为对照组(n=41)和观察组(n=42),对照组行rhBNP治疗,观察组采用rhBNP联合左西孟旦治疗,比较两组治疗后的临床疗效及安全性。结果:两组治疗后的NT-ProBNP水平均低于治疗前,LVEF水平均高于治疗前,且观察组治疗后的NTProBNP水平低于对照组同期,LVEF水平高于对照组同期(P<0.05),两组治疗前后的LVEDD水平无明显差异。观察组和对照组治疗后的临床总有效率无明显差异(95.2%vs 87.8%,P>0.05);但观察组治疗后临床疗效优于对照组(P<0.05)。两组安全性指标无明显差异(P>0.05)。结论:rhBNP联合左西孟旦治疗急性失代偿性心力衰竭可明显提高治疗效果,且安全性高。

Objective ：To explore the clinical efficacy and safety of recombinant human brain natriuretic peptide（rhBNP） combined with levosimendan in the treatment of patients with acute decompensated heart failure. Methods ：83 Patients with acute decompensated heart failure from Jan 2015 to Jan 2016 were randomly divided into control group（n=41） and observation group（n=42）. The observation group were treated by rh BNP combined with levosimendan when control group were underwent treatment of rhBNP. Comparisons of clinical efficacy and safety between two groups after treatment were conducted. Results ：The NT-ProBNP levels of two groups after treatment were lower than those before treatment, and the LVEF levels of two groups after treatment were higher than those before treatment, the difference was statistically significant（P〈0.05）. NT-ProBNP levels in observation group after treatment were lower than those of control group, and the LVEF levels in observation group after treatment were higher than those in control group（P〈0.05）. The clinical efficacy of observation group was better than that of control group by the rank-sum test.Conclusion： rhBNP combined with levosimendanin the treatment of patients with acute decompensated heart failure has good clinical efficacy and safety.